Presentation (CTI)

OBJECTIVES: Real-world effectiveness data for Zunveyl®(Benzgalantamine) as treatment for dementia in the long-term care (LTC) setting are sparse. The lack of data on changes in cognition, behavior, or sleep quality among patients in LTC settings is due to the difficulty of obtaining complete information from charts or claims. The BEACON study will obtain insights from clinicians with experience treating dementia (e.g., Geri-Psychiatrists) within LTC regarding outcomes of interest and the most efficient way to capture them.
METHODS: This mixed-method study will focus on two primary objectives: To gain insight from the Study Steering Panel (SSP) on the dementia treatment outcomes of interest and to identify the best sources to capture them. To gain insight from clinicians into changes in outcomes of interest following treatment with Zunveyl® compared with previously used cholinesterase inhibitor products.The patient demographics, treatment history, and any data demonstrating effectiveness will be captured via chart review using the ASKr platform, a secure, asynchronous, social media-style app designed to capture healthcare professional perspectives and sensitive information.When response data are not available in the chart, the clinician can rely on recall to document outcomes. For ease of capture and consistency, there will be multiple-choice answers
RESULTS: At submission, the consensus survey results that focus on how to determine clinical effectiveness retrospectively are available. At the time of the presentation, the complete dataset will be available, and the full results will be shared.
CONCLUSIONS: Real-world outcome data for patients with dementia in long-term care is not easily available, but this novel approach allows for valuable data to be compiled for large numbers of patients efficiently and provides opportunities for unique clinical insights into real-world drug effectiveness in the LTC setting.